BAF180 (pBRM) and BAF200 (Arid2), which are present in the same pBAF complex, are both frequently mutated in liver cancers (94), and about 18% of hepatitis-associated hepatocellular carcinomas have mutations in BAF200 (94). In other exome sequencing studies, PBRM1, ARID2, and BAP1 were found to be inactivated in a large proportion of specific liver cancers [LCB (liver cancer displaying biliary phenotype)]. This finding suggests that they might work together cooperatively to contribute to the pathogenesis of this tumor (95).
